The Coca-Cola Company — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone Q4 report; the provided filing text does not give a clear Q4-only financial summary.
Business context
Coca-Cola is a global beverage company operating in more than 200 countries and territories. It primarily sells concentrates and syrups to independent bottlers, alongside finished beverages through consolidated bottling operations, Costa retail stores and other channels. Worldwide system unit-case volume was 33.3 billion, up from 32.7 billion in 2022.
Key financial results
| Metric | 2023 | 2022 | Change |
|---|---|---|---|
| Net operating revenues | $45.754 billion | $43.004 billion | +6% |
| Gross profit | $27.234 billion | $25.004 billion | +9% |
| Operating income | $11.311 billion | $10.909 billion | +4% |
| Net income attributable to Coca-Cola shareowners | $10.714 billion | $9.542 billion | +12% |
| Diluted EPS | $2.47 | $2.19 | +13% |
| Cash provided by operating activities | $11.599 billion | $11.018 billion | +5% |
- Margins: Gross margin rose to 59.5% from 58.1%; operating margin declined to 24.7% from 25.4%. Pricing and favorable channel/package mix supported gross margin; commodity costs, higher marketing and operating charges, and currency headwinds pressured operating margin.
- Revenue drivers: Volume contributed 2% growth, price/product/geographic mix 10%, foreign exchange reduced revenue 4%, and acquisitions/divestitures reduced it 1% (rounded). Latin America revenue rose 19%; Europe, Middle East and Africa rose 7%; North America rose 7%; Asia Pacific was flat.
- Cash generation and investment: Capital expenditures were $1.852 billion, making operating cash flow less capital expenditures approximately $9.747 billion. Investing activities used $3.349 billion; financing activities used $8.310 billion.
- Liquidity: Cash, cash equivalents, short-term investments and marketable securities totaled $13.7 billion. Current assets were $26.732 billion versus current liabilities of $23.571 billion, or a current ratio of approximately 1.13. The company also reported $4.6 billion of unused corporate backup credit lines.
- Debt: Year-end loans and notes payable were $4.557 billion, current maturities of long-term debt $1.960 billion, and long-term debt $35.547 billion. Long-term debt, including current maturities, had a carrying value of $37.507 billion. Interest expense rose 73% to $1.527 billion, primarily reflecting higher rates on short-term borrowings and derivatives. Ratings were A+ (S&P) and A1 (Moody’s).
- Capital returns: Dividends paid were $7.952 billion and share repurchases were $2.289 billion. In February 2024, the board raised the quarterly dividend to $0.485 per share, or $1.94 annualized.
Material changes and unusual items
- Net operating revenues increased 6%, while unit-case and concentrate-sales volume each grew 2%; growth therefore relied substantially on pricing and mix.
- Other operating charges increased to $1.951 billion from $1.215 billion. The main item was a $1.702 billion charge from remeasuring fairlife acquisition contingent consideration, versus $1.000 billion in 2022. The remaining fairlife liability was $3.017 billion at year-end and is contingent on results through 2024, with any final milestone payment due in 2025.
- Other income included a $439 million gain from refranchising Vietnam bottling operations and a $94 million gain on sales of equity-method interests in Pakistan and Indonesia. These items, along with investment-security gains and other items, benefited reported results.
- Foreign exchange reduced revenue by 4% and operating income by 8%. Interest expense rose sharply year over year.
- The company refranchised Vietnam operations and classified bottling operations in the Philippines, Bangladesh and parts of India as held for sale, with refranchising expected in Q1 2024.
Outlook, risks and contingencies
- The filing does not provide a clear quantified 2024 revenue or EPS growth forecast in the supplied text. Management expects foreign-exchange movements to adversely affect 2024 revenue based on spot rates and hedging coverage.
- Management expects 2024 capital expenditures of approximately $2.2 billion and an effective tax rate of approximately 19.2%, before significant operating or nonoperating items. The tax-rate estimate excludes any adverse outcome in the IRS litigation.
- IRS transfer-pricing dispute: The Tax Court opinions largely favored the IRS for 2007–2009, and the company plans to appeal. Coca-Cola recorded a $439 million reserve, but estimates potential aggregate incremental tax and interest of approximately $16 billion if the Tax Court methodology were upheld and applied to later years through 2023. The company estimates it may have to pay approximately $5.8 billion, plus further interest, for 2007–2009 following the Tax Court decision; some or all could be refunded if it prevails on appeal. The company says it believes its positions are more likely than not to be sustained on appeal.
- Management cites inflation and input-cost pressures, currency volatility, competition, consumer health and product preferences, supply-chain and commodity risks, water scarcity, climate and packaging regulation, and cybersecurity/privacy risks. It expects inflationary pressure on certain costs to continue in 2024.
- Other noteworthy exposure: the $1.702 billion fairlife contingent-consideration remeasurement charge and assumptions behind impairment testing, including BodyArmor’s trademark, whose fair value approximated carrying value at year-end.
Most important facts for investors to verify
- Progress and potential cash-payment timing in the IRS dispute; distinguish the $439 million recorded reserve from the much larger conditional exposure.
- Whether price increases can continue to offset inflation and commodity costs without materially weakening volume or consumer demand.
- Whether 2024 currency headwinds and higher interest expense will continue to pressure operating income and margins.
- Fairlife performance against milestone targets and the resulting contingent-consideration liability and future cash payment.
- Execution and proceeds from planned bottling refranchising, and the company’s ability to sustain cash generation while funding dividends, capital spending and repurchases.